Varicella vaccine studies in healthy children and adults.
Immunization of normal children and adults with Oka strain live varicella vaccine from several manufacturers has been studied in our laboratory and elsewhere. This paper summarizes clinical trials designed to obtain information on minimum dose immunogenicity pre- and postexposure prophylaxis, immunization of various age groups, and booster immunizations for seropositive individuals. These studies documented a 94% to 100% seroconversion rate with 95% to 100% persistence of antibodies at 3 to 4 years. Protective efficacy was more than 90%, and the vaccine was successful in preventing varicella when a high dose was given postexposure. Clinical reactions were limited to temperature elevations and minor papulovesicular rashes that occurred in 5% to 10% of vaccinees. Herpes zoster has been absent in vaccinated healthy individuals.
D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D002644:Chickenpox / Q000517:prevention & control / Q000635:transmission; D019433:Chickenpox Vaccine; D002648:Child; D004341:Drug Evaluation; D005500:Follow-Up Studies; D006562:Herpes Zoster / Q000209:etiology; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007117:Immunization, Secondary; D014765:Viral Vaccines / Q000008:administration & dosage / Q000009:adverse effects
D000914:Antibodies, Viral; D019433:Chickenpox Vaccine; D014765:Viral Vaccines